Amos Stemmer

648 total citations
19 papers, 387 citations indexed

About

Amos Stemmer is a scholar working on Oncology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amos Stemmer has authored 19 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Infectious Diseases and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amos Stemmer's work include SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Amos Stemmer is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Amos Stemmer collaborates with scholars based in Israel, United States and Australia. Amos Stemmer's co-authors include Salomon M. Stemmer, Noa Eliakim‐Raz, Neta Moskovits, Shlomit Yust‐Katz, Alona Zer, Haim Ben‐Zvi, Alexandra Benouaich‐Amiel, Adva Levy‐Barda, Tal Zaks and Jihad Bishara and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Amos Stemmer

19 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amos Stemmer Israel 8 278 201 60 38 37 19 387
Hagit Padova Israel 7 229 0.8× 98 0.5× 83 1.4× 14 0.4× 20 0.5× 14 366
Noëlle Cognard France 9 262 0.9× 67 0.3× 54 0.9× 28 0.7× 19 0.5× 15 412
Simone De Nitto Italy 9 254 0.9× 46 0.2× 15 0.3× 39 1.0× 19 0.5× 24 336
Tina Thomson United Kingdom 7 213 0.8× 40 0.2× 29 0.5× 38 1.0× 12 0.3× 10 319
Gordon Hay United Kingdom 12 170 0.6× 100 0.5× 10 0.2× 57 1.5× 23 0.6× 30 524
Lohith Gowda United States 11 178 0.6× 186 0.9× 12 0.2× 29 0.8× 15 0.4× 35 439
Sigrun Einarsdottir Sweden 9 160 0.6× 141 0.7× 23 0.4× 139 3.7× 18 0.5× 22 438
Ellen Araj United States 7 168 0.6× 25 0.1× 24 0.4× 15 0.4× 49 1.3× 14 256
A. Meerveld-Eggink Netherlands 11 68 0.2× 71 0.4× 22 0.4× 106 2.8× 58 1.6× 20 283
Simon Eschweiler United Kingdom 4 257 0.9× 85 0.4× 10 0.2× 34 0.9× 29 0.8× 5 449

Countries citing papers authored by Amos Stemmer

Since Specialization
Citations

This map shows the geographic impact of Amos Stemmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amos Stemmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amos Stemmer more than expected).

Fields of papers citing papers by Amos Stemmer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amos Stemmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amos Stemmer. The network helps show where Amos Stemmer may publish in the future.

Co-authorship network of co-authors of Amos Stemmer

This figure shows the co-authorship network connecting the top 25 collaborators of Amos Stemmer. A scholar is included among the top collaborators of Amos Stemmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amos Stemmer. Amos Stemmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Shulman, Eldad D., Amos Stemmer, Beibei Ru, et al.. (2025). Abstract 6353: Path2Space: An AI approach for cancer biomarker discovery via histopathology inferred spatial transcriptomics. Cancer Research. 85(8_Supplement_1). 6353–6353. 1 indexed citations
2.
Margalit, Ofer, Amos Stemmer, William J. Chapin, et al.. (2024). Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. European Journal of Cancer. 212. 114336–114336. 4 indexed citations
3.
Stemmer, Amos, et al.. (2023). Predictive biomarkers for response to immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer.. Journal of Clinical Oncology. 41(4_suppl). 254–254. 1 indexed citations
4.
Stemmer, Amos, Ofer Margalit, Jane V. Thomas, et al.. (2023). Immunotherapy in mismatch repair-deficient metastatic colorectal cancer – Outcome and novel predictive markers. European Journal of Cancer. 198. 113495–113495. 5 indexed citations
5.
Eliakim‐Raz, Noa, Amos Stemmer, Noam Erez, et al.. (2022). Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study. BMJ Open. 12(8). e061584–e061584. 4 indexed citations
6.
Barda, Noam, Noa Dagan, Amos Stemmer, et al.. (2022). Improving Cardiovascular Disease Prediction Using Automated Coronary Artery Calcium Scoring from Existing Chest CTs. Journal of Digital Imaging. 35(4). 962–969. 4 indexed citations
7.
8.
Bar‐Haim, Erez, Noa Eliakim‐Raz, Amos Stemmer, et al.. (2022). Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years. Journal of Clinical Medicine. 11(9). 2649–2649. 3 indexed citations
9.
Sagie, Shira, et al.. (2022). Real-world evidence for immunotherapy in the first line setting in small cell lung cancer. Lung Cancer. 172. 136–141. 22 indexed citations
10.
Tschernichovsky, Roi, Amos Stemmer, Alexandra Benouaich‐Amiel, et al.. (2022). Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. Journal of Neuro-Oncology. 156(3). 483–489. 4 indexed citations
11.
Elnekave, Eldad, Sivan Shamai, Elchanan Bruckheimer, et al.. (2022). Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study. Cancers. 14(20). 5045–5045. 10 indexed citations
12.
Eliakim‐Raz, Noa, et al.. (2022). Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults. JAMA Network Open. 5(7). e2223090–e2223090. 16 indexed citations
13.
Eliakim‐Raz, Noa, et al.. (2021). Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment. JAMA Oncology. 7(11). 1716–1716. 31 indexed citations
14.
Eliakim‐Raz, Noa, Amos Stemmer, Adva Levy‐Barda, et al.. (2021). Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncology. 7(8). 1133–1133. 170 indexed citations
15.
Onn, Amir, Teodor Gottfried, Amos Stemmer, et al.. (2021). Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer. Cancers. 13(11). 2800–2800. 5 indexed citations
16.
Eliakim‐Raz, Noa, et al.. (2021). Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years. JAMA. 326(21). 2203–2203. 67 indexed citations
17.
18.
Stemmer, Amos, Inbal Shafran, Salomon M. Stemmer, & Daliah Tsoref. (2020). Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. Cancers. 12(10). 3026–3026. 10 indexed citations
19.
Stemmer, Amos, et al.. (2019). Current and Potential Approaches for Defining Disease Signatures: a Systematic Review. Journal of Molecular Neuroscience. 67(4). 550–558. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hagit Padova Breakdown of academic impact, for papers by Noëlle Cognard Breakdown of academic impact, for papers by Simone De Nitto Breakdown of academic impact, for papers by Tina Thomson Breakdown of academic impact, for papers by Gordon Hay Breakdown of academic impact, for papers by Lohith Gowda Breakdown of academic impact, for papers by Sigrun Einarsdottir Breakdown of academic impact, for papers by Ellen Araj Breakdown of academic impact, for papers by A. Meerveld-Eggink Breakdown of academic impact, for papers by Simon Eschweiler
Rankless by CCL
2026